Pyrimidine Derivatives Patents

13 patents (2 US, 2 European for 5 countries each, 1 Chinese), additional abandoned or expired patent family members, 2002 priority date

  1. General Details

    The patent portfolio, owned by a leading innovative pharmaceutical company, addresses a broad range of pyrimidine derivatives useful for pharmaceutical and other applications. Pharmaceutical applications for humans exhibit ZAP-70, Focal Adhesion Kynase (FAK) and Syk protein tyrosine kinsases inhibiting activity.  Pyrimidine drugs are known to provide the following properties: anticancer, antibacterial, antiprotozoal, antimicrobial, antiviral, antihypertensive, antihistaminic, anti-inflammatory, analgesic, CNS-active to metabolic adjuvants.

  2. Patent Portfolio
    • 1 Patent Family
    • 13 Patents
    • Additional Patent Family Members (see accompanying spreadsheet)
    • 2002, earliest priority date
    • United States, Europe (Germany, Great Britain, France, Italy, Spain) and China
    • Blockbuster, orphan drug and rare disease pharmaceuticals for ZAP-70, FAK and Syk protein tyrosine kinases inhibition
    • Sample companies cited/citing patent portfolio: Abbott, Amgen, Astrazeneca, Bayer Pharmaceuticals, Berlex Laboratories, Celltech Therapeutics, Eli Lilly and Company, Janssen, Novartis, Pfizer, Rigel Pharmaceuticals, Schering, The Scripps Research Institute, Smithkline Beecham, Yamanouchi Pharmaceutical
  3. Claim Charts & Licensees
    • Claim charts available
    • 18+ potential licensees (sample, non-comprehensive list)
  4. Pricing, Data Room Access & Additional Details

    Data room access is available upon signing Vibrant IP’s standard buyer and nondisclosure agreement.

    • Docket Listing of Patents and Applications
    • Patent and Application PDFs
    • File Wrappers / File Histories
    • Detailed Description of Portfolio
    • Claim Charts
    • Potential Licensees and Related Entities
    • Additional Information

    Contact sales@vibrantip.com for pricing guidance, data room access, and additional information.

  5. Documents